secwatch.observer — SEC 8-K summary
======================================

Issuer:     Scienture Holdings, Inc. (SCNX)
CIK:        0001382574
Form:       8-K
Filed at:   2023-07-31T23:59:59+00:00
Accession:  0001493152-23-026024
Event type: m_and_a
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 2.01, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

TRxADE closes Superlatus acquisition, regains Nasdaq compliance
---------------------------------------------------------------

- Acquired Superlatus; shareholders received 136,441 common shares (19.99% stake) and 306,855 Series B Preferred (100:1 conversion).
- Issued MEDS Rights: 7 rights per share held on July 28, 2023; each right allows one free common share upon signing registration rights agreement.
- Appointed Candice Beaumont as director; she is Superlatus's Executive Director with 20+ years in finance, banking, M&A.
- Regained compliance with Nasdaq's $2.5M minimum stockholders' equity requirement under listing rule 5550(b)(1).
- Lock-up agreements: 360-day restriction on sale/transfer of shares for certain Superlatus and MEDS stockholders.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1382574/000149315223026024/0001493152-23-026024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1382574/000149315223026024/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-026024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer